
Cataract
Latest News

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with Ophthalmology Times, Randall Olson, MD, lead author and a Distinguished Professor at the University of Utah, Chair of the Department of Ophthalmology and Visual Sciences, and CEO of the John A. Moran Eye Center, discusses the ongoing research.

HelpMeSee launches global effort to combat cataract blindness and empower women in low-income countries
Video Series

CME Content

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

The integration of artificial intelligence in laser cataract technology is shifting the paradigm for the future of cataract surgery and is driving increased precision and improved outcomes for patients.

George O. Waring, IV, MD, provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster was titled, "Two-Year Clinical Feasibility Trial Outcomes for a Dual-Optic IOL System for the Treatment of Presbyopia and Cataract."

Investigators conducted a retrospective clinical database study that covered 12 years to quantify the risk of PCR in the second eye after PCR developed in the first eye during cataract surgery.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

News
According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.

The Gni instrument technology represents a significant innovation in ophthalmic surgery, particularly in cataract procedures, according to Gulani.

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding


The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs

A team of researchers in China examined the difference and relationship between optical coherence tomography and optical quality analysis system parameters induced by compound electrolyte intraocular irrigating solution or Ringer lactate solution during uncomplicated cataract surgery.

According to the company, its combined vitreoretinal-cataract system and standalone cataract system are cleared for use in the United States.

Investigators looked to see if a large language model could provide safe, accurate, and readable information to patient inquiries about cataract surgery.

Over 380 organizations representing patients, health care providers, the medical technology and biopharmaceutical industry, health plans and others endorse the legislation

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

The organization is providing free cataract resources for patients and professionals, including fact sheets, social media graphics, a dedicated web page and expert video.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

Abbreviated New Drug Applications seek potential approval of a generic drug product.

The AIOLIS will be used to clinically evaluate patients’ perception of visual disturbances following premium IOL cataract surgery.

The company’s KDB GLIDE is indicated for the excision of trabecular meshwork tissue to reduce intraocular pressure in adult patients with primary open-angle glaucoma during cataract surgery or as a stand-alone procedure.

This research ultimately could enhance the manufacture of eye implants universally used in cataract and refractive surgeries.























